This post was originally published on this site
https://i-invdn-com.investing.com/trkd-images/LYNXMPEI6K05R_L.jpg
Chairman Christoph Franz will not seek re-election after nine years as board chairman at the next annual shareholder meeting in March 2023, the Swiss drugmaker said in a statement on Thursday.
In a separate scheduled release, Roche said first-half adjusted operating income rose a better-than-expected 9% on higher sales of diagnostic tests and pharmaceuticals.
Core operating income, which is adjusted for one-off effects, gained 9% to 12.67 billion Swiss francs ($13.07 billion), the Swiss drugmaker said in a statement on Thursday, above an analyst consensus of 12.1 billion francs.
It confirmed its full-year guidance.
Under Schinecker’s leadership, the diagnostics business saw a surge in demand for COVID-19 test kits during the pandemic, which has been easing during the second quarter.
Roche reaffirmed that sales of COVID-19 medicines and diagnostics would decrease by about 2 billion Swiss francs this year to around 5 billion francs.
Schwan has been a member of the executive committee since 2006 and has served as CEO since 2008, overseeing a strong share price performance.
